Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer.
Continued androgen receptor (AR) signaling is an established mechanism underlying castration-resistant prostate cancer (CRPC), and suppression of androgen receptor signaling remains a therapeutic goal of CRPC therapy. Constitutively active androgen receptor splice variants (AR-Vs) lack the androgen receptor ligand-binding domain (AR-LBD), the intended target of androgen deprivation therapies including CRPC therapies such as abiraterone and MDV3100. While the canonical full-length androgen receptor (AR-FL) and AR-Vs are both increased in CRPCs, their expression regulation, associated transcriptional programs, and functional relationships have not been dissected. In this study, we show that suppression of ligand-mediated AR-FL signaling by targeting AR-LBD leads to increased AR-V expression in two cell line models of CRPCs. Importantly, treatment-induced AR-Vs activated a distinct expression signature enriched for cell-cycle genes without requiring the presence of AR-FL. Conversely, activation of AR-FL signaling suppressed the AR-Vs signature and activated expression programs mainly associated with macromolecular synthesis, metabolism, and differentiation. In prostate cancer cells and CRPC xenografts treated with MDV3100 or abiraterone, increased expression of two constitutively active AR-Vs, AR-V7 and ARV567ES, but not AR-FL, paralleled increased expression of the androgen receptor-driven cell-cycle gene UBE2C. Expression of AR-V7, but not AR-FL, was positively correlated with UBE2C in clinical CRPC specimens. Together, our findings support an adaptive shift toward AR-V-mediated signaling in a subset of CRPC tumors as the AR-LBD is rendered inactive, suggesting an important mechanism contributing to drug resistance to CRPC therapy.
Department of Urology, Johns Hopkins University, Baltimore, Maryland, USA.
Rong
R
Hu
Changxue
C
Lu
Elahe A
EA
Mostaghel
Srinivasan
S
Yegnasubramanian
Meltem
M
Gurel
Clare
C
Tannahill
Joanne
J
Edwards
William B
WB
Isaacs
Peter S
PS
Nelson
Eric
E
Bluemn
Stephen R
SR
Plymate
Jun
J
Luo
D000736:Androstenes; D000737:Androstenols / Q000494:pharmacology; D000818:Animals; D001549:Benzamides; D002369:Castration; D045744:Cell Line, Tumor; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008024:Ligands; D008297:Male; D051379:Mice; D009376:Neoplasms, Hormone-Dependent / Q000378:metabolism*; D009570:Nitriles; D010669:Phenylthiohydantoin / Q000031:analogs & derivatives / Q000494:pharmacology; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism; D020033:Protein Isoforms / Q000378:metabolism*; D017434:Protein Structure, Tertiary; D011944:Receptors, Androgen / Q000235:genetics / Q000378:metabolism*; D015398:Signal Transduction; D014158:Transcription, Genetic; D014183:Transplantation, Heterologous; D044763:Ubiquitin-Conjugating Enzymes / Q000235:genetics
D000736:Androstenes; D000737:Androstenols; D001549:Benzamides; D008024:Ligands; D009570:Nitriles; D020033:Protein Isoforms; D011944:Receptors, Androgen; D010669:Phenylthiohydantoin; C540278:enzalutamide; C105156:UBE2C protein, human; D044763:Ubiquitin-Conjugating Enzymes; C089740:abiraterone